2019-06-20
FDA grants Camurus IND application to enter Phase 3 study with CAM2029 for treatment of acromegaly
The FDA has approved Camurus’ Investigational New Drug application to initiate a Phase 3 study with CAM2029 once-monthly octreotide subcutaneous depot for treatment of acromegaly.
The study will be performed at around 50 clinical sites in the US and in Europe and is expected to be completed early 2021.
Read more at Camurus’ website: https://www.camurus.com/pressreleases/